List view / Grid view
![AstraZeneca sign and logo on company building exterior - South San Francisco, California, US in 2020 [Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/AstraZeneca-4-300x278.jpg)
![AstraZeneca sign and logo on company building exterior - South San Francisco, California, US in 2020 [Credit: Michael Vi/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/AstraZeneca-4.jpg)
H1 financial results show AstraZeneca’s revenues grew by 23 percent…
H1 financial results show AstraZeneca’s revenues grew by 23 percent in 2021, with $14.37 billion attributed to activities aside from COVID-19 vaccine sales.
After manufacturing delays, AstraZeneca will now provide the EU with…
After manufacturing delays, AstraZeneca will now provide the EU with the 40 million COVID-19 vaccine doses it originally agreed to supply.
Interim analysis shows AZD1222 vaccine is effective at preventing COVID-19,…
Interim analysis shows AZD1222 vaccine is effective at preventing COVID-19, with no severe cases or hospitalisations reported more than 21 days after first injection.
Clinical trials for AZD1222, the AstraZeneca COVID-19 vaccine candidate, have…
Clinical trials for AZD1222, the AstraZeneca COVID-19 vaccine candidate, have resumed across the world after confirmation it is safe to do so.
After the clinical trial for AZD1222 was halted last week,…
After the clinical trial for AZD1222 was halted last week, the studies for AstraZeneca's COVID-19 vaccine candidate will now resume.
An agreement between AstraZeneca and the European Commission means the…
An agreement between AstraZeneca and the European Commission means the company will supply up to 400 million doses of its AZD1222 COVID-19 vaccine.
AstraZeneca plans to produce up to 400 million doses of…
AstraZeneca plans to produce up to 400 million doses of the University of Oxford’s COVID-19 vaccine candidate, with deliveries to begin by the end of the year.
Pharma executives are committed to bringing drugs to market to…
Pharma executives are committed to bringing drugs to market to improve the lives of patients but is the industry too introspective to be truly innovative?
The vaccine alliance said the Covax AMC programme is the…
The vaccine alliance said the Covax AMC programme is the first in a series of financing programmes to ensure low- and middle-income countries will have access to COVID-19 vaccines.
A new agreement between the University of Oxford and AstraZeneca…
A new agreement between the University of Oxford and AstraZeneca will allow the former's COVID-19 vaccine candidate to be manufactured and distributed.
AstraZeneca’s new carbon emission plan includes a 100 percent electric…
AstraZeneca’s new carbon emission plan includes a 100 percent electric vehicle fleet and a 50 million tree reforestation plan.
The FDA has approved Fasenra for the add-on maintenance treatment of…
The FDA has approved Fasenra for the add-on maintenance treatment of patients with severe asthma aged 12 years and older...
Following the news earlier this week that AstraZeneca had been…
Following the news earlier this week that AstraZeneca had been in acquisition talks with Acerta Pharma, AstraZeneca today announced that it is to invest in a majority equity stake in the company.
"Following a thorough and extensive search it became clear that…
"Following a thorough and extensive search it became clear that Marc possessed the rare blend of financial, business and science experience..."
AstraZeneca today announced that Pascal Soriot has been appointed as…
AstraZeneca today announced that Pascal Soriot has been appointed as the company’s Chief Executive Officer. Pascal Soriot will take on his new responsibilities and join the AstraZeneca PLC Board as an Executive Director on 1 October 2012.
